恰加斯病和 COVID-19 中的免疫血栓调节紊乱：抗凝的对比研究。
Immunothrombotic dysregulation in chagas disease and COVID-19: a comparative study of anticoagulation.
机构信息
Centro de Investigación Facultad de Medicina UNAM-UABJO, Facultad de Medicina y Cirugía, Universidad Autónoma Benito Juárez de Oaxaca, Oaxaca, 68020, México.
CONACYT Facultad de Medicina y Cirugía, Universidad Autónoma, Benito Juárez de, Oaxaca, 68020, México.
出版信息
Mol Cell Biochem. 2021 Oct;476(10):3815-3825. doi: 10.1007/s11010-021-04204-3. Epub 2021 Jun 10.
Abstract
Chagas and COVID-19 are diseases caused by Trypanosoma cruzi and SARS-CoV-2, respectively. These diseases present very different etiological agents despite showing similarities such as susceptibility/risk factors, pathogen-associated molecular patterns (PAMPs), recognition of glycosaminoglycans, inflammation, vascular leakage hypercoagulability, microthrombosis, and endotheliopathy; all of which suggest, in part, treatments with similar principles. Here, both diseases are compared, focusing mainly on the characteristics related to dysregulated immunothrombosis. Given the in-depth investigation of molecules and mechanisms related to microthrombosis in COVID-19, it is necessary to reconsider a prompt treatment of Chagas disease with oral anticoagulants.
摘要
恰加斯病和 COVID-19 分别由克氏锥虫和 SARS-CoV-2 引起。这两种疾病的病因截然不同，但也存在一些相似之处，如易感/危险因素、病原体相关分子模式（PAMPs）、糖胺聚糖识别、炎症、血管渗漏、高凝、微血栓形成和血管内皮病变；所有这些都在一定程度上提示治疗原则相似。在这里，将对这两种疾病进行比较，主要侧重于与免疫血栓失调相关的特征。鉴于 COVID-19 中对与微血栓形成相关的分子和机制的深入研究，有必要重新考虑对恰加斯病进行快速抗凝治疗。
相似文献
1
Immunothrombotic dysregulation in chagas disease and COVID-19: a comparative study of anticoagulation.恰加斯病和 COVID-19 中的免疫血栓调节紊乱：抗凝的对比研究。
Mol Cell Biochem. 2021 Oct;476(10):3815-3825. doi: 10.1007/s11010-021-04204-3. Epub 2021 Jun 10.
2
Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection.疫苗诱导的免疫性血栓性血小板减少症（VITT）与自然 SARS-CoV-2 感染中免疫血栓形成的机制比较。
J Autoimmun. 2021 Jul;121:102662. doi: 10.1016/j.jaut.2021.102662. Epub 2021 May 19.
3
Re. Re.: "Immunothrombotic dysregulation in Chagas disease and COVID19: a comparative study of anticoagulation".关于：“恰加斯病和 COVID19 中的免疫血栓调节紊乱：抗凝比较研究”的回复。
Mol Cell Biochem. 2023 Feb;478(2):361-362. doi: 10.1007/s11010-022-04511-3. Epub 2022 Jul 13.
4
Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy.新型冠状病毒肺炎肺炎中的免疫血栓调节紊乱与呼吸衰竭和凝血病有关。
Circulation. 2020 Sep 22;142(12):1176-1189. doi: 10.1161/CIRCULATIONAHA.120.048488. Epub 2020 Jul 28.
5
Antibodies and complement are key drivers of thrombosis.抗体和补体是血栓形成的关键驱动因素。
Immunity. 2024 Sep 10;57(9):2140-2156.e10. doi: 10.1016/j.immuni.2024.08.007. Epub 2024 Sep 2.
6
Emerging Role of Platelet-Endothelium Interactions in the Pathogenesis of Severe SARS-CoV-2 Infection-Associated Myocardial Injury.血小板-内皮细胞相互作用在严重 SARS-CoV-2 感染相关心肌损伤发病机制中的新作用。
Front Immunol. 2022 Feb 4;13:776861. doi: 10.3389/fimmu.2022.776861. eCollection 2022.
7
Change in platelet indices in patients with Coronavirus disease-2019 (COVID-19): A reflection of platelet activation and contribution to immunothrombosis?2019冠状病毒病（COVID-19）患者血小板指标的变化：血小板活化的反映及其对免疫性血栓形成的作用？
Int J Lab Hematol. 2022 Feb;44(1):e46-e48. doi: 10.1111/ijlh.13705. Epub 2021 Sep 24.
8
Re: "Immunothrombotic dysregulation in chagas disease and COVID‑19: a comparative study of anticoagulation".关于：“恰加斯病和新冠肺炎中的免疫血栓调节异常：抗凝治疗的比较研究”
Mol Cell Biochem. 2022 Apr;477(4):1093-1094. doi: 10.1007/s11010-022-04361-z. Epub 2022 Jan 20.
9
Immunothrombosis in COVID-19: Implications of Neutrophil Extracellular Traps.COVID-19 中的免疫血栓形成：中性粒细胞胞外陷阱的影响。
Biomolecules. 2021 May 6;11(5):694. doi: 10.3390/biom11050694.
10
Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets.抗 SARS-CoV-2 刺突 IgG 的异常糖基化是血小板的促血栓形成刺激物。
Blood. 2021 Oct 21;138(16):1481-1489. doi: 10.1182/blood.2021011871.
引用本文的文献
1
The Functions of Cytokines in the Cardiac Immunopathogenesis of Chagas Disease.细胞因子在恰加斯病心脏免疫发病机制中的作用
Pathogens. 2024 Oct 3;13(10):870. doi: 10.3390/pathogens13100870.
2
Right-Sided Cardiac Thrombosis and Pulmonary Thromboembolism in Chronic Chagas Disease: A Review of Clinical Features and Post-Mortem Examination.慢性恰加斯病中的右侧心脏血栓形成和肺血栓栓塞：临床特征与尸检综述
Rev Cardiovasc Med. 2024 Jun 19;25(6):220. doi: 10.31083/j.rcm2506220. eCollection 2024 Jun.
3
SBC Guideline on the Diagnosis and Treatment of Patients with Cardiomyopathy of Chagas Disease - 2023.巴西心脏病学会2023年恰加斯病心肌病患者诊断与治疗指南
Arq Bras Cardiol. 2023 Jun 26;120(6):e20230269. doi: 10.36660/abc.20230269.
4
Challenges of addressing neglected tropical diseases amidst the COVID-19 pandemic in Africa: A case of Chagas Disease.非洲新冠疫情期间应对被忽视热带病的挑战：以恰加斯病为例
Ann Med Surg (Lond). 2022 Sep;81:104414. doi: 10.1016/j.amsu.2022.104414. Epub 2022 Aug 20.
5
Management of Cardiovascular Disease in Patients With COVID-19 and Chronic Chagas Disease: Implications to Prevent a Scourge Still Larger.新冠病毒病合并慢性恰加斯病患者的心血管疾病管理：预防更大灾难的启示
Front Med (Lausanne). 2022 Jun 29;9:910388. doi: 10.3389/fmed.2022.910388. eCollection 2022.
本文引用的文献
1
Ethnic disparities in COVID-19 mortality in Mexico: A cross-sectional study based on national data.墨西哥 COVID-19 死亡率的种族差异：基于国家数据的横断面研究。
PLoS One. 2021 Mar 10;16(3):e0239168. doi: 10.1371/journal.pone.0239168. eCollection 2021.
2
ABO blood type association with SARS-CoV-2 infection mortality: A single-center population in New York City.ABO 血型与 SARS-CoV-2 感染死亡率的关联：纽约市的单中心人群研究。
Transfusion. 2021 Apr;61(4):1064-1070. doi: 10.1111/trf.16339. Epub 2021 Mar 5.
3
Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors.中国 COVID-19 患者合并症的患病率：危险因素的系统评价和荟萃分析。
BMC Infect Dis. 2021 Feb 22;21(1):200. doi: 10.1186/s12879-021-05915-0.
4
A preliminary study of platelet hyperactivity in the chronic indeterminate phase of Chagas' disease.恰加斯病慢性不确定期血小板活性亢进的初步研究。
Trop Biomed. 2018 Sep 1;35(3):678-683.
5
Deep vein thrombosis in COVID-19 patients in general wards: prevalence and association with clinical and laboratory variables.普通病房中 COVID-19 患者的深静脉血栓形成：患病率及与临床和实验室变量的关联。
Radiol Med. 2021 May;126(5):722-728. doi: 10.1007/s11547-020-01312-w. Epub 2021 Jan 19.
6
Myocardial Inflammation and Dysfunction in COVID-19-Associated Myocardial Injury.新型冠状病毒病相关心肌损伤中的心肌炎症与功能障碍。
Circ Cardiovasc Imaging. 2021 Jan;14(1):e012220. doi: 10.1161/CIRCIMAGING.120.011713. Epub 2021 Jan 19.
7
Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation.贝加莫省新冠肺炎康复者：急性后期门诊再评估
Epidemiol Infect. 2021 Jan 19;149:e32. doi: 10.1017/S0950268821000145.
8
Pulmonary thrombosis in Covid-19: before, during and after hospital admission.新冠病毒肺炎中的肺血栓形成：入院前、住院期间及出院后
J Thromb Thrombolysis. 2021 May;51(4):978-984. doi: 10.1007/s11239-020-02370-7. Epub 2021 Jan 1.
9
Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin.肝素抑制 SARS-CoV-2 的细胞侵袭：刺突 S1 受体结合域与肝素相互作用的结构依赖性。
Thromb Haemost. 2020 Dec;120(12):1700-1715. doi: 10.1055/s-0040-1721319. Epub 2020 Dec 23.
10
High prevalence of occult thrombosis in cases of mild/moderate COVID-19.轻度/中度 COVID-19 病例中隐匿性血栓形成的高患病率。
Int J Infect Dis. 2021 Mar;104:77-82. doi: 10.1016/j.ijid.2020.12.042. Epub 2020 Dec 19.
Zotero 插件